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Replication of the hepatitis B virus is suppressed by defi-
ciency of the X protein. Although several molecules that block
cellular targets of X protein reduce the production of hepatitis
B virus progeny, the effect of a specific inhibitor of X protein
on viral replication has not been investigated. To block X
protein specifically, we adopted an intracellular expression
approach using H7 single chain variable fragment (H7scFv), an
antibody fragment against X protein. We previously demon-
strated that cytoplasmic expression of H7scFv inhibits X pro-
tein-induced tumorigenicity and transactivation. In this study,
intracellular H7scFv expression inhibits reporter gene transac-
tivation but not viral replication determined by endogenous
hepatitis B virus polymerase activity assay and real-time PCR.
Our findings imply that intracellular expression of antibody
fragment against X protein may not be an alternative thera-
peutic modality for inhibition of hepatitis B virus replication.
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INTRODUCTION
The control of replication of the hepatitis B
virus (HBV) is important because HBV persis-
tently infects more than 300 million people and is
a principal cause of liver cancer.
1 HBV has relaxed
circular DNA containing four open reading frames
encoding three structural proteins (the poly-
merase, core, and surface proteins) and one non-
structural protein, X protein (HBx). Upon infection
of hepatocytes, viral DNA is transported to the
nucleus where it is converted to a covalently closed,
circular, double-stranded DNA (cccDNA). Genomic
and subgenomic viral transcripts, all of which
utilize the same polyadenylation signal and con-
tain the HBx gene sequence, are transcribed from
cccDNA. The largest HBV transcript is encap-
sidated in cytoplasmic core particles, within which
reverse transcription and DNA replication occur.
Mature enveloped viral particles are eventually
secreted from the infected cells.
2
The importance of HBx in HBV replication has
previously been reported. In HepG2 cells, the level
of core particles of wild type virus was higher than
that of a HBx deletional mutant.
3,4 HBx can en-
hance viral replication in HBV transgenic mice,
apparently through activation of viral gene expres-
sion.
5 HBx has been shown to affect HBV replica-
tion through a proteasome-dependent pathway.
6
Additionally, HBx acts on stored cytosolic calcium
and activates Pyk2, which is critical for stimulation
of HBV DNA replication in tissue culture.
4 Similar
to HBV, woodchuck hepatitis virus X protein is
also required for viral infection in vivo.
7
In addition to its role in viral replication, an
oncogenic function of HBx has been demon-
strated. HBx transactivates viral and host genes
and stimulates the Ras-Raf-MEK-ERK signal trans-
duction pathway.
8,9 HBx expression in NIH-3T3
cells leads these cells to develop tumors in nude
mice, and hepatocellular carcinomas develop in
HBx transgenic mice.
10,11 Previously, we showed
that HBx-mediated tumorigenicity is suppressed
by interfering with HBx function through intracel-
lular expression of the H7 antibody single chain
variable fragment (scFv) against HBx.
12
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Although several agents that block cellular
targets of HBx reduce HBV replication, it remains
an open question whether specific inhibitors of
HBx may affect viral replication.
4 In the present
study, we investigated the effect of intracellular
expression of H7scFv on HBV replication.
MATERIALS AND METHODS
Vectors
The eukaryotic expression vectors for H7scFv,
with specificity to HBx, and for S2E1scFv, with spe-
cificity to surface protein of HBV, were described
previously.
12 Briefly, variable gene segments of the
immunoglobulin heavy and light chain of H7 and
S2E1 respectively were linked by a (GGGGS)3
flexible peptide linker. These constructs contain a
Myc epitope adjacent to the N-terminus of each
scFv that facilitates the detection of expressed
proteins. Using NheI and XhoI sites, each myc
tagged scFv gene was subcloned into pIRES-EGFP
(Clonetech, Mountain View, CA, U.S.A.).
Cells and transfection
The HepG2-WT10 cell line that stably produces
HBV (kindly provided by Dr. Cheng, Yale Univer-
sity School of Medicine, New Haven, Connecticut,
U.S.A.) was cultured in DMEM (GIBCO BRL, MD)
supplemented with 10% fetal bovine serum (GIBCO
BRL, Carlsbad, California, U.S.A.).
13 Cells (3 × 10
6)
were seeded into a 10-cm-diameter culture dish and
then transfected with 8 g of empty vector (pCMV- μ
Myc or pIRES-EGFP), H7scFv-expressing vector
(pCMV-Myc-H7scFv or pIRES-H7scFv), or S2E1-ex-
pressing vector (pCMV-Myc-S2E1scFv or pIRES-
S2E1) using Lipofectamine 2000 reagent (GIBCO
BRL, Carlsbad, California, U.S.A.). All experiments
were performed using both the pCMV vector series
and pIRES vector series except the HBe Ag assay,
which used the pIRES vector series.
Western blot analysis
HepG2-WT10 cells were transfected with H7sc
Fv-expressing plasmid or control plasmid (pCMV-
Myc-S2E1scFv or pCMV-Myc). After 48 hours, the
cell lysates were separated on 12% SDS-PAGE,
transferred to PVDF membranes and reacted with
murine anti-Myc Ab for scFv or anti-tubulin Ab
(Calbiochem, Darmstadt, Germany) as an internal
control. Bound Ab was detected with horseradish
peroxidase conjugated anti-mouse Ig antibody
and an ECL detection system (Amersham,
Piscataway, NJ, U.S.A.).
Preparation of intracellular and extracellular
HBV DNA
For the analysis of extracellular viral progeny
DNA, HepG2-WT10 cells were transfected with
pCMV-Myc, pCMV-Myc-H7scFv or pCMV-Myc-
S2E1scFv and two days later the cell medium was
harvested. The virus was precipitated by 10%
polyethylene glycol 8000 in 0.5 M NaCl and 60
mM EDTA at 4 overnight. After centrifugation,
the virus was resuspended in protein kinase
buffer (PKB; 10 mM Tris-Cl (pH 7.8), 5 mM EDTA,
0.5% SDS) and digested with 100 g/mL prote μ -
inase K (Sigma, St. Louis, MO, U.S.A.) for 1 hr at
37 . DNA was purified by phenol/chloroform
extraction and ethanol precipitation.
For the preparation of intracellular viral pro-
geny DNA, HepG2-WT10 cells were lysed with 1
mL lysis buffer (10 mM Tris-Cl (pH 8), 1 mM
EDTA, 1% NP-40, 50 mM NaCl) on ice for 10 min.
The lysate was centrifuged for 2 min at 12,000g
and the supernatant was treated with 10 U/mL
DNase I (Takara, Kyoto, Japan) and 30 U/mL
micrococcal nuclease (Calbiochem, San Diego, CA,
U.S.A.), for 30 min at 37 . A 4 concentration of
PNE buffer (26% polyethylene glycol, 1.4 M NaCl,
40 mM EDTA) was added and the mixture was
incubated for 1 hr on ice prior to centrifugation
at 12,000g for 15 min. The DNA was isolated by
digestion with 100 g/ mL proteinase K (Sigma, μ
St. Louis, MO, U.S.A.) in PKB for 1 hr at 37 ,
followed by a phenol/chloroform extraction and
ethanol precipitation.
Real-time PCR
To analyze the effect of intracellular H7scFv on
HBV replication, the amount of viral core DNA
was measured using real-time PCR. Intracellular
and extracellular core particles were obtainedIntracellular Antibody and HBV Replication
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from HepG2-WT10 cells transiently expressing
H7scFv or control S2E1. Cells were cultured for 48
hours prior to treatment with 100 g/mL pro μ -
teinase K (Sigma, St. Louis, MO, U.S.A.) for 1 hr
at 37 and DNA extraction using phenol/ chloro-
form and ethanol precipitation. Real-time PCR
was performed on viral DNA as described pre-
viously.
14 The amplification-detection was carried
out in an ABI PRISM 7000 Sequence Detector
(Applied Biosystem, Foster City, CA, U.S.A.).
Endogeneous polymerase assay (EPA)
Cytosolic core particles were isolated from equal
numbers of HepG2-WT10 cells transfected with H7
scFv-expressing plasmid or control plasmid, and
subjected to endogenous HBV polymerase activity
assay (EPA) as previously described.
15 Briefly, core
particles were precipitated from cell lysates with
6.5% polyethylene glycol, incubated with EPA
reaction buffer containing 10 Ci [ - μ α
32P]-dATP (3000
Ci/mmol) at 37 overnight, and resolved by gel
electrophoresis and autoradiography.
Analysis of HBeAg production
HepG2-WT10 cells were transfected with H7sc
Fv-expressing plasmid or control plasmid. After
48 hours in culture, supernatants were harvested
and subjected to ELISA for HBeAg (DaiSorin
S.P.A., Saluggia, Italy).
Indirect immunofluorescence microscopy
HepG2-WT10 cells grown on coverslips were
fixed in 4% formaldehyde for 15 min and per-
meabilized in 0.2% Triton X-100. After 15 min the
cells were incubated with murine monoclonal
anti-Myc Ab (Clontech, Mountain View, CA,
U.S.A.) overnight at 4 , followed by incubation
with FITC-conjugated anti-mouse IgG Ab (Jackson
Immuno Research Laboratories Inc., West Grove,
Pennsylvania, U.S.A.) at room temperature for 1 hr.
Cells were examined with a fluorescence micro-
scope (Olympus BX60, Tokyo, Japan).
Luciferase activity assay
HepG2-WT10 cells or HepG2 cells (2 × 10
5)
were seeded into 24-well plates. After 16 hr, cells
were co-transfected with pGL3-Control vector
(Promega, Madison, WI, U.S.A.) containing the
luciferase gene under the control of an SV40
enhancer/promoter and pCMV-Myc, pCMV-Myc-
H7scFv or pCMV-Myc-S2E1scFv. After 24 hr or 48
hr, cells were harvested and lysed in 50 L 1 μ ×
Passive Lysis Buffer (Promega, Madison, WI,
U.S.A.). The cell lysate (5 L) was mixed with 25 μ
L of Luciferase Assay Reagent II (Promega, μ
Madison, WI, U.S.A.) and the light intensity was
measured using a luminometer (Turner Designs,
Sunnyvale, CA, U.S.A.).
RESULTS
Intracellular scFv expression
HBx is expressed primarily in the cytoplasm of
cells.
16,17 Previously, we demonstrated that cyto-
plasmic expression of H7scFv, an antibody frag-
ment specific for HBX, suppresses HBx-induced
tumorigenicity and transactivation.
12 Thus, to
block HBx function in cells in which HBV repli-
cation occurs, H7scFv was expressed in the
cytoplasm of HepG2-WT10 cells. As a control,
S2E1scFv specific to the small surface glycopro-
tein (HBsAg) of HBV was used. S2E1scFv in the
cytoplasm neither interacts with HBx nor inter-
feres with HBx function in fibroblasts expressing
HBx.
12 It was reported by others that an antibody
fragment specific to HBsAg interfered with
HBsAg secretion when it was expressed in the
ER, but not in the cytoplasm, of Huh-7 cells.
18
We confirmed that intracytoplasmic expression of
S2E1scFv has no effect on HBsAg production by
HepG2-WT10 (data not shown). As shown in Fig.
1A, we observed an scFv band of approximately
30 kDa in each lysate from cells transfected with
scFv-expressing plasmid. Cytoplasmic localiza-
tion of H7scFv and S2E1scFv in transfected cells
is shown in Fig. 1B.
Effect of intracellular expression of H7scFv on
HBeAg secretion
Since the levels of HBeAg in patients' serum
have shown correlation with viral replication, weYoung-Hee Jin, et al.
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next examined the effect of intracellular expression
of H7scFv on the secretion of HBeAg by HepG2-
WT10 cells.
14 HBeAg production by Hep G2-WT10
cells transfected with plasmid expressing H7scFv
was similar to that of controls transfected with
empty vector or plasmid expressing S2E1scFv (Fig.
2). These results suggest that the suppression of
HBx function has no effect on the production of
HBeAg. According to Zhang's results using a HBx
deletional mutant, HBeAg secretion by cultured
cells was not affected by the expression of HBx,
despite the reduced viral replication of the HBx
deletional mutant.
7
Effect of intracellular expression of H7scFv on
HBV replication
We analyzed the effect of intracellular H7scFv-
expression on HBV replication using EPA.
Cytosolic core particles were isolated from equal
numbers of HepG2-WT10 cells transfected with
H7scFv-expressing plasmid or control plasmid
and subjected to EPA. The endogenous HBV
polymerase activity obtained from cells expressing
H7scFv was slightly decreased compared with
cells containing empty vector, but similar to that
of cells expressing S2E1scFv (Fig. 3). The relative
level of endogenous HBV polymerase activity
from cells expressing H7scFv to that from cells
transfected with empty vector varied between
experiments, with a maximum reduction of about
16% (data not shown). However, the endogenous
HBV polymerase activity from cells expressing
H7scFv was consistently similar to that from cells
expressing S2E1scFv (data not shown). These
Fig. 1. Intracellular expression of H7scFv. (A) HepG2-WT10 cells were transiently transfected with H7scFv-expression
plasmid or control plasmid (empty vector or S2E1scFv-expression plasmid). After 48 hours, the lysate of transfected cells
was analyzed by Western blotting with anti-Myc-Ab (upper) and anti-tubulin Ab (lower). (B) HepG2-WT10 cells were
transfected with H7scFv expression plasmid or control plasmid. One day after transfection, scFv protein in the cytoplasm
was visualized by immunofluorescence microscopy using anti-Myc Ab and FITC-conjugated rabbit affinity purified Ab
to mouse IgG.
Fig. 2. HBeAg production was not affected by intracellular
expression of H7scFv. Culture medium was harvested and
analyzed by ELISA for HBeAg 48 hours after transfection
of HepG2-WT10 cells with pIRES-H7scFv or control
plasmid (pIRES-EGFP or pIRES-S2E1).
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results suggest that the expression of H7scFv
inside cells to block HBx function may have no
effect on the formation of cytoplasmic core par-
ticles.
To further analyze the effect of intracellular
H7scFv-expression on HBV replication, the pro-
duction of extracellular core particles and intra-
cellular core particles was assessed by real-time
PCR (Fig. 4). Serially diluted HBV DNA was
amplified to give a standard curve, which was
constructed by plotting the relative cycle thresh-
old values against the known DNA copy number
of each standard. The standard curve showed
good regression (correlation coefficient r = 0.98,
slope = -3.3). The copy number of each sample
was calculated using the standard curve, and
those of intracellular HBV core DNA were about
10 fold higher than that of extracellular HBV core
DNA. As shown in Fig. 4, the copy numbers of
both intracellular and extracellular HBV core
DNA from cells expressing H7scFv were not re-
duced compared with those from cells containing
control plasmids. These results indicated that
intracellular H7scFv-expression has no effect on
HBV replication.
Suppressive effect of intracellular H7scFv ex-
pression on transactivation in HepG2-WT10 cells
To show the suppressive effect of intracellular
H7scFv on HBx function in HepG2-WT10 cells, a
luciferase reporter assay was performed. Lucif-
erase activity increased with increased amount of
transfected plasmid containing luciferase gene
(Fig. 5A). Luciferase activity was higher in
HepG2-WT10 cells than in HepG2 cells on both
day 1 and day 2. A much higher luciferase activity
was observed in HepG2-WT10 cells on day 2 than
on day 1. These results suggest transactivation of
the luciferase gene by viral proteins such as HBx.
We next assessed luciferase activity in cells co-
transfected with plasmid expressing scFv and
plasmid containing the luciferase gene. As ex-
pected, luciferase activity was lower in HepG2-
WT10 cells expressing H7scFv than in cells co-
transfected with empty vector (Fig. 5). Unex-
pectedly, luciferase activity was also lower in
HepG2-WT10 cells expressing S2E1scFv than in
cells co-transfected with empty vector.
Fig. 3. Expression of intracellular H7scFv did not influence
endogenous HBV polymerase activity. Cytoplasmic core
particles were isolated from HepG2-WT10 cells transiently
expressing H7scv or S2E1scFv, incubated with buffer con-
taining [ - α
32P]dATP and visualized by gel electrophoresis
and autoradiography. Relative band intensity was plotted.
Fig. 4. Intracellular expression of H7scFv had no effect on
HBV replication. HepG2-WT10 cells were transfected with
pIRES-H7scFv or control plasmid. Forty-eight hours later,
intracellular and extracellular core particles were isolated
and viral DNA was amplified by real-time PCR. At the
same time, serially diluted HBV plasmid samples were
amplified for the construction of a standard curve (cor-
relation coefficient r = 0.98, slope = -3.3). HBV DNA copy
numbers were calculated using the standard curve and
cycle threshold. The bar indicates the mean value of three
different experiments. Similar results were obtained using
the pCMV vector series.
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DISCUSSION
The present study was triggered by our pre-
vious work showing that intracellular H7scFv-
expression suppresses HBx-mediated tumori-
genicity.
12 In this study, H7scFv expression inside
HepG2-WT10 cells did not affect HBV replication
even though it reduced gene transactivation in
this cell line compared with cells transfected with
control vector. Several intracellular Abs specific to
viral proteins important in viral replication have
been reported to affect viral lifecycles. Intracel-
lular scFv against hepatitis B virus core protein
suppresses viral replication in a HB611 cell line.
19
With respect to human immunodeficiency virus,
functional suppression of Vif protein, matrix pro-
tein p17, tat or gp120 by intracellular expression
of a specific Ab fragment inhibits virus prolifera-
tion.
20,21 However, in this study intracellular H7sc
Fv targeting HBx did not affect viral replication.
HBx has been shown to enhance HBV repli-
cation in various experimental systems, but not in
all systems. The viral progeny DNA level of a
HBx deletional mutant was reduced to ~ 10% of
that of wild type virus.
4,7 Furthermore, HBx does
not play a role in HBV replication in a Huh-7 cell-
based system or a HBV transgenic mouse
system.
7,22,23 Thus, the significance of HBx in HBV
replication is likely to depend on the experimental
system, and it is possible that HBx is not critical
in our experimental system.
We expressed H7scFv in the cytoplasm of Hep
G2-WT10 cells. Considering that HBx is present in
the nucleus at very low expression levels but
becomes mostly cytoplasmic at increased expres-
sion levels,
16 and that HBx likely interacts with or
acts on the mitochondrial transition pore,
24 the
minor fraction of HBx in the nucleus or in
Fig. 5. Intracellular H7scFv expression suppressed transactivation in HepG2-WT10 cells. (A) To demonstrate transactivation
of a gene under the SV40 enhancer/promoter in HepG2-WT10 cells, luciferase activity was measured in cells transfected
with the indicated amount of pGL3-Control vector. Increased luciferase activity was observed in HepG2-WT10 cells
compared with HepG2 cells. The experiments were repeated three times and similar trends were observed in each case.
(B) Luciferase activity was measured at the indicated time after co-transfection of HepG2 cells and HepG2-WT10 cells with
pGL3-Control vector and H7scFv expression plasmid, S2E1scFv or empty vector. Relative luciferase activity shows the
percentage of relative light units of the sample with respect to relative light units of WT10 cells transfected with empty
vector. The mean percentage of triplicates with standard errors is shown. The experiments were repeated two times and
similar trends were observed in each case.
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mitochondria may not be affected by cytoplasmic
H7scFv-expression. A recent report shows that
HBx in association with DDB1 acts in the nucleus
and stimulates HBV replication in HepG2 cells.
25
Further study is needed to clarify whether intra-
nuclear expression of H7scFv can inhibit HBV
replication.
In this study we indirectly show the inhibitory
effect of intracellular H7scFv expression on HBx
function by the assay of reporter gene activity.
The interaction of H7scFv with HBx inside cells
and the inhibitory effect of H7scfv on HBx-in-
duced gene activation was previously demon-
strated.
12 Interestingly, intracellular S2E1scFv ex-
pression also suppressed transactivation of the
reporter gene in HBV-replicating HepG2-WT10
cells. A previous study reported that intracellular
expression of S2E1scFv in NHBx1 cells that ex-
press HBx did not affect transactivation of a re-
porter gene.
12 At present we cannot explain these
findings, but we suggest one possibility. Since the
target antigen of S2E1scFv is HBsAg, it is possible
that S2E1scFv may recognize a polymerase and
surface fusion protein, P-S fusion protein, a 43-kD
protein containing epitopes of the N-terminus of
polymerase and most parts of surface protein and
which is encoded by a spliced RNA.
26 Although
transactivation of this P-S fusion protein has not
yet been studied, P-S fusion protein cannot be
ruled out based on the transcriptional activation
of truncated middle surface (preS2/S) protein.
27,28
In addition, at this point we cannot exclude the
possibility that the expression of scFv itself affects
transactivation of the reporter gene inside HepG2-
WT10 cells.
In summary, we show that H7scFv-expression
inside HBV-replicating cells inhibits reporter gene
transactivation but not HBV replication. Our find-
ings imply that the targeting of HBx by intra-
cellular expression of an antibody fragment may
not be effective for the control of HBV replication.
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